Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer.

JCO precision oncology - 1 Jan 2021

Henry Jason T, Coker Oluwadara, Chowdhury Saikat, Shen John Paul, Morris Van K, Dasari Arvind, Raghav Kanwal, Nusrat Maliha, Kee Bryan, Parseghian Christine, Pant Shubham, Jeyakumar Nikeshan, Zhu Limin, Nishioka Yujiro, Fogelman David, Wolff Robert A, Hong David, Overman Michael J, Vauthey JeanNicolas, Kopetz Scott, Johnson Benny

Abstract excerpt

PURPOSE: KRAS p.G12C mutations occur in approximately 3% of metastatic colorectal cancers (mCRC). Recently, two allosteric inhibitors of KRAS p.G12C have demonstrated activity in early phase clinical trials. There are no robust studies examining the behavior of this newly targetable population. METHODS: We queried the MD Anderson Cancer Center data set for patients with colorectal cancer who harbored KRAS p.G12C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 34250391
DOI: 10.1200/PO.20.00256
PMCID: PMC8232253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer.PMID 34250391Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation.Semantic proximity Read ↗

Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.Semantic proximity Read ↗

Landscape of KRAS G12C , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS -Mutated CancersSemantic proximity Read ↗

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancerSemantic proximity Read ↗

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.Semantic proximity Read ↗

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.